US 12,076,421 B2
Assessment of coronary heart disease with carbon dioxide
Rohan Dharmakumar, Moorpark, CA (US); Debiao Li, San Marino, CA (US); and Sotirios A. Tsaftaris, Lucca (IT)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
Filed on Aug. 31, 2021, as Appl. No. 17/463,073.
Application 17/463,073 is a continuation of application No. 15/910,718, filed on Mar. 2, 2018, granted, now 11,129,911.
Application 15/910,718 is a continuation in part of application No. 15/672,162, filed on Aug. 8, 2017, abandoned.
Application 15/672,162 is a continuation of application No. 14/075,918, filed on Nov. 8, 2013, abandoned.
Application 14/075,918 is a continuation in part of application No. 14/115,860, granted, now 11,439,309, previously published as PCT/US2012/036813, filed on May 7, 2012.
Claims priority of provisional application 61/482,956, filed on May 5, 2011.
Prior Publication US 2022/0054661 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 49/08 (2006.01); A61K 31/7076 (2006.01); A61K 33/00 (2006.01)
CPC A61K 49/08 (2013.01) [A61K 31/7076 (2013.01); A61K 33/00 (2013.01); A61K 2300/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of inducing hyperemia in a subject in need thereof, comprising:
administering a carbon dioxide (CO2)-containing gas to the subject;
attaining at least one increase in the subject's coronary arterial partial pressure of carbon dioxide (PaCO2), to induce a vasoreactive response in the subject; and
imaging the heart of the subject for a number of repeated measurements during a period of time in which the at least one increase in the PaCO2 is measurable, to produce imaging data indicative of a vascular reactivity corresponding to the vasoreactive response in at least one coronary blood vessel or region of the heart, wherein the number of repeated measurements is sufficient to produce a statistical significance at p-value <0.05 in measuring a difference of the vascular reactivity compared to baseline in response to the at least one increase in coronary PaCO2.